Inventors:
Mark Gustavson - Greensboro NC, US
Jason Christiansen - Glastonbury CT, US
Anthony Martin Magliocco - Tampa FL, US
Assignee:
UTI Limited Partnership - Alberta CA
HistoRx, Inc. - Branford CT
International Classification:
G01N 33/68
Abstract:
Disclosed herein are methods of identifying suitable patients for postoperative radiotherapy based on the discovery that the quantification of ER, beyond simple positive/negative characterization, can provide valuable predictive information for the treatment of cancer, specifically breast cancer, and more particularly may predict a group more likely to respond to RT and spare patients from a potentially harmful treatment. Furthermore, the true quantification of ER expression provides a continuous recurrence risk assessment for patients being treated with tamoxifen, and therefore the standardization of the data across sites and imaging platforms significantly reduces the misclassification of patients when compared to the current standard by which ER expression is determined.